Avidity Biosciences Inc. (RNA) Receives IND Clearance from FDA to Proceed with the Phase 1/2 MARINA™ Trial of AOC 1001 in Adults with Myotonic Dystrophy
Go back to Avidity Biosciences Inc. (RNA) Receives IND Clearance from FDA to Proceed with the Phase 1/2 MARINA™ Trial of AOC 1001 in Adults with Myotonic Dystrophy| PROSENSA HOLD (NASDAQ: RNA) | Delayed: 8.95 -0.61 (6.38%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.56 | 52 Week High | $22.80 | |||
| Open | $9.57 | 52 Week Low | $4.12 | |||
| Day High | $9.67 | P/E | N/A | |||
| Day Low | $8.66 | EPS | $0.00 | |||
| Volume | 1,036,990 | |||||
